The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...

Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.

Of three enzymes encoded by HIV–reverse transcriptase, protease, and integrase—only the first two have been exploited clinically as inhibitor targets. Efforts to develop inhibitors of purified ...

REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

Thermo Fisher Scientific Inc. TMO recently launched its Applied Biosystems HIV-1 Genotyping Kit with Integrase. This research only evaluates positive human immunodeficiency virus (HIV) samples to ...

On June 5, 1981, national health experts published accounts of a strange infection circulating around Los Angeles. The U.S. Centers for Disease Control and Prevention (CDC) reported on that day that, ...

FDA Announces Baraclude (entecavir) is Not Recommended for HIV/HBV Co-infected Patients Who Are Not Also Receiving HAART Due to the Potential for the Development of HIV Resistance ROCKVILLE, Md., Aug.

Impact of medicaid-enrollment status/timing on stage at diagnosis among male cancer patients. Background: A 21-gene RT-PCR assay (the assay) has been recommended to predict the risk of recurrence and ...

Regimen for treatment-experienced patients Use treatment history, past and current resistance profiles, and identifiable causes of treatment failure to design new regimen with at least 2 (preferably 3 ...